Predictive Significance of Promoter DNA Methylation of Cysteine Dioxygenase Type 1 (CDO1) in Metachronous Gastric Cancer |
Kubota, Yo
(Department of Gastroenterology, Kitasato University School of Medicine)
Tanabe, Satoshi (Division of Therapeutic Endoscopy, Department of Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine) Azuma, Mizutomo (Department of Gastroenterology, Kitasato University School of Medicine) Horio, Kazue (Department of Gastroenterology, Kitasato University School of Medicine) Fujiyama, Yoshiki (Division of Advanced Surgical Oncology, Department of Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine) Soeno, Takafumi (Division of Advanced Surgical Oncology, Department of Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine) Furue, Yasuaki (Department of Gastroenterology, Kitasato University School of Medicine) Wada, Takuya (Department of Gastroenterology, Kitasato University School of Medicine) Watanabe, Akinori (Department of Gastroenterology, Kitasato University School of Medicine) Ishido, Kenji (Department of Gastroenterology, Kitasato University School of Medicine) Katada, Chikatoshi (Department of Gastroenterology, Kitasato University School of Medicine) Yamashita, Keishi (Division of Advanced Surgical Oncology, Department of Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine) Koizumi, Wasaburo (Department of Gastroenterology, Kitasato University School of Medicine) Kusano, Chika (Department of Gastroenterology, Kitasato University School of Medicine) |
1 | Kojima K, Yamashita K, Ushiku H, Katoh H, Ishii S, Tanaka T, et al. The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. Dis Esophagus 2017;30:1-9. |
2 | Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969;1:87-97. DOI |
3 | Kojima K, Nakamura T, Ooizumi Y, Igarashi K, Tanaka T, Yokoi K, et al. Clinical significance of cancer specific methylation of the CDO1 gene in small bowel cancer. PLoS One 2019;14:e0211108. DOI |
4 | Kojima K, Nakamura T, Ohbu M, Katoh H, Ooizumi Y, Igarashi K, et al. Cysteine dioxygenase type 1 (CDO1) gene promoter methylation during the adenoma-carcinoma sequence in colorectal cancer. PLoS One 2018;13:e0194785. DOI |
5 | Yamashita K, Waraya M, Kim MS, Sidransky D, Katada N, Sato T, et al. Detection of methylated CDO1 in plasma of colorectal cancer; a PCR study. PLoS One 2014;9:e113546. DOI |
6 | Quach DT, Hiyama T. Assessment of endoscopic gastric atrophy according to the Kimura-Takemoto classification and its potential application in daily practice. Clin Endosc 2019;52:321-327. DOI |
7 | Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011;19:387-400. DOI |
8 | Kojima K, Minatani N, Ushiku H, Ishii S, Tanaka T, Yokoi K, et al. Prediction of onset of remnant gastric cancer by promoter DNA methylation of CDO1/HOPX/Reprimo/E-cadherin. Oncotarget 2019;10:2423-2434. DOI |
9 | Fujiyama Y, Kumamoto Y, Nishizawa N, Nakamoto S, Harada H, Yokota K, et al. Promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in intraductal papillary mucinous neoplasm (IPMN). Ann Surg Oncol 2020;27:4007-4016. DOI |
10 | Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M, et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer 2009;124:2367-2374. DOI |
11 | Nishizawa N, Harada H, Kumamoto Y, Kaizu T, Katoh H, Tajima H, et al. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer. Cancer Sci 2019;110:2846-2855. DOI |
12 | Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2019;5:1749-1768. DOI |
13 | Yamashita S, Kishino T, Takahashi T, Shimazu T, Charvat H, Kakugawa Y, et al. Genetic and epigenetic alterations in normal tissues have differential impacts on cancer risk among tissues. Proc Natl Acad Sci U S A 2018;115:1328-1333. DOI |
14 | Kimura K, Satoh K, Ido K, Taniguchi Y, Takimoto T, Takemoto T. Gastritis in the Japanese stomach. Scand J Gastroenterol Suppl 1996;31:17-20. DOI |
15 | Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2015;45:884-891. DOI |
16 | Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021;24:1-21. DOI |
17 | Nakajima T, Oda I, Gotoda T, Hamanaka H, Eguchi T, Yokoi C, et al. Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance? Gastric Cancer 2006;9:93-98. DOI |
18 | Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of Helicobacter pylori eradication on the incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial. Lancet 2008;372:392-397. DOI |
19 | Mori G, Nakajima T, Asada K, Shimazu T, Yamamichi N, Maekita T, et al. Incidence of and risk factors for metachronous gastric cancer after endoscopic resection and successful Helicobacter pylori eradication: results of a large-scale, multicenter cohort study in Japan. Gastric Cancer 2016;19:911-918. DOI |
20 | Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-209. DOI |
21 | Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999;59:5438-5442. |
22 | Brait M, Ling S, Nagpal JK, Chang X, Park HL, Lee J, et al. Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers. PLoS One 2012;7:e44951. DOI |
23 | Maeda M, Nakajima T, Oda I, Shimazu T, Yamamichi N, Maekita T, et al. High impact of methylation accumulation on metachronous gastric cancer: 5-year follow-up of a multicentre prospective cohort study. Gut 2017;66:1721-1723. DOI |
24 | Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994;7:536-540. DOI |
25 | Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 2010;70:1430-1440. DOI |
26 | Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006;12:989-995. DOI |
27 | Ushijima T, Hattori N. Molecular pathways: involvement of Helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers. Clin Cancer Res 2012;18:923-929. DOI |
28 | Ushijima T, Asada K. Aberrant DNA methylation in contrast with mutations. Cancer Sci 2010;101:300-305. DOI |
29 | Yamashita K, Hosoda K, Nishizawa N, Katoh H, Watanabe M. Epigenetic biomarkers of promoter DNA methylation in the new era of cancer treatment. Cancer Sci 2018;109:3695-3706. DOI |
30 | Kang YP, Torrente L, Falzone A, Elkins CM, Liu M, Asara JM, et al. Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer. eLife 2019;8:e45572. DOI |
31 | Asada K, Nakajima T, Shimazu T, Yamamichi N, Maekita T, Yokoi C, et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut 2015;64:388-396. DOI |
32 | Harada H, Hosoda K, Moriya H, Mieno H, Ema A, Ushiku H, et al. Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer. PLoS One 2019;14:e0214872. DOI |
33 | Ushiku H, Yamashita K, Ema A, Minatani N, Kikuchi M, Kojo K, et al. DNA diagnosis of peritoneal fluid cytology test by CDO1 promoter DNA hypermethylation in gastric cancer. Gastric Cancer 2017;20:784-792. DOI |
34 | Ushiku H, Yamashita K, Katoh H, Ema A, Minatani N, Kikuchi M, et al. Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma. Dis Esophagus 2017;30:1-9. |
35 | Kamada T, Hata J, Sugiu K, Kusunoki H, Ito M, Tanaka S, et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther 2005;21:1121-1126. DOI |
![]() |